Prospective memory deficit associated with major depressive disorder: Causality, clinical impact, and potential molecular mechanisms
Year: 2026
Type: article
Study design: Observational Study
Abstract: < 0.05). Among 134 patients with follow-up, linear mixed-effects models revealed slower HAMD reduction in patients with PM deficits (z = 2.287, P = 0.022). PM performance showed no significant change after treatment (P = 0.117). To investigate potential mechanisms and therapeutics, shared targets for MDD and PM were identified through network pharmacology and summary-data-based MR, revealing Rap1 signaling as the top enriched pathway with eight core targets. Molecular docking showed relatively weak predicted affinities (mean > -7.5 kcal/mol) of commonly used antidepressants to these targets. Virtual screening of psychiatric compounds identified Hypericin, with strong affinity to the core targets (mean -9.06 kcal/mol). In conclusion, MDD may increase the risk of PM deficits, which are associated with poorer treatment response and show limited improvement following current antidepressant treatments. Rap1-related mechanisms may be involved, and Hypericin may be considered a compound for further investigation.
Source: Neurotherapeutics
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7225851073
